SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations

More>>

Kumar, P., Lee, S.K., Shankar, P. and Manjunath, N. (2006) A Single siRNA Suppresses Fatal Encephalitis Induced by Two Different Flaviviruses. PLoS Medicine, 3, e96.
http://dx.doi.org/10.1371/journal.pmed.0030096

has been cited by the following article:

  • TITLE: Japanese Encephalitis Virus Replication and Inhibitory Effect of shRNA in Mice

    AUTHORS: Manabu Murakami, Takafumi Tasaki, Souichi Nukuzuma, Hiroshi Minato, Takayuki Nojima, Yasuhito Ishigaki, Tsutomu Takegami

    KEYWORDS: Japanese Encephalitis Virus, Mice, shRNA, Antiviral

    JOURNAL NAME: Advances in Microbiology, Vol.6 No.6, May 20, 2016

    ABSTRACT: Japanese Encephalitis Virus (JEV) is responsible for over 30,000 annual cases of encephalitis worldwide, causing 30% mortality. JEV is thus a continuing threat to public health, so development of new antiviral drugs against JEV is desirable. Here, we examined JEV replication in mouse and used a short hairpin RNA JRi as the antiviral agent. The features of virus replication in neuron and survival rates of mice infected with JEV were different between virus strains. The mice infected with the virulent JEV strain (JaGAr01) were injected with pJRi (100 μg/mouse) which produced shRNAJRi. The survival rates of mice treated at 3 days before, the same day and 3 days after JEV infection were 22%, 78% and 44%, respectively. In addition, we demonstrated that the injection of pJRi induced interferon (IFN) production in cells and mice. These results suggest that the replication of JEV can be efficiently inhibited by RNAi and innate immunity including IFN. These data mean that pJRi has the inhibitory activity against JEV infection in vivo, and could be used as an antiviral drug to treat JEV infection.